Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rotavirus multi-antigen vaccine (Symvivo)
- Development stage
- Preclinical
- Lead developer
- Symvivo
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Biotherapeutic Products → Microbiome Therapeutics, Gene Therapies
- Administration
- Oral, Intravenous
01
Overview
Rotavirus multi-antigen vaccine (Symvivo) is an investigational DNA vaccine being developed by Symvivo for the prevention of rotavirus infections. The vaccine utilizes Symvivo's proprietary **bacTRL™** platform, which employs engineered probiotic bacteria (*Bifidobacterium longum*) to deliver plasmid DNA encoding multiple rotavirus antigens directly to the patient's cells. This bacterial-mediated gene delivery system is designed for both oral and intravenous administration. Once the plasmid is delivered, the patient's own cells express the viral antigens, potentially eliciting a robust and protective mucosal and systemic immune response. This approach aims to overcome the stability and safety limitations associated with traditional live-attenuated rotavirus vaccines.
- Other names
- Symvivo rotavirus vaccinebacTRL rotavirus vaccine
02
Targets
RVA (Rotavirus A)DNA
Beyond the preview
Go deeper on Rotavirus multi-antigen vaccine (Symvivo).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rotavirus multi-antigen vaccine (Symvivo).